Dr. Behnam Badie
Claim this profileCity of Hope Medical Center
Studies Glioblastoma
Studies Brain Cancer
6 reported clinical trials
9 drugs studied
Area of expertise
1Glioblastoma
Stage IV
IL13Rα2 positive
Stage III
2Brain Cancer
Stage IV
IL13Rα2 positive
IL13R alpha 2
Affiliated Hospitals
Clinical Trials Behnam Badie is currently running
CAR T-Cell Therapy
for Brain Cancer
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.
Recruiting1 award Phase 122 criteria
CAR T-Cell Therapy + Immunotherapy
for Glioblastoma
This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms that may attack specific glioma cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving IL13Ralpha2-CAR T cells and nivolumab together may work better in treating patients with glioblastoma.
Recruiting1 award Phase 120 criteria
More about Behnam Badie
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Behnam Badie has experience with
- IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
- Ipilimumab
- Nivolumab
- Chimeric Antigen Receptor (CAR) T Cells With A Chlorotoxin Tumor-Targeting Domain
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- HER2(EQ)BBζ/CD19t+ T Cells
Breakdown of trials Behnam Badie has run
Glioblastoma
Brain Cancer
Relapse
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Behnam Badie specialize in?
Behnam Badie focuses on Glioblastoma and Brain Cancer. In particular, much of their work with Glioblastoma has involved Stage IV patients, or patients who are IL13Rα2 positive.
Is Behnam Badie currently recruiting for clinical trials?
Yes, Behnam Badie is currently recruiting for 2 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Behnam Badie has studied deeply?
Yes, Behnam Badie has studied treatments such as IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab.
What is the best way to schedule an appointment with Behnam Badie?
Apply for one of the trials that Behnam Badie is conducting.
What is the office address of Behnam Badie?
The office of Behnam Badie is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.